The NAT2 test is used to help predict how your body metabolizes, or breaks down, the medication amifampridine (Firdapse). Poor metabolizers (also called “slow acetylators”) do not break down the medication to the same extent as rapid (fast) metabolizers (also called “fast or rapid acetylators”) and should be initiated on the lowest recommended starting dose and closely monitored for side effects.
